Role of Adjuvant Therapy in Esophageal Cancer Patients After Neoadjuvant Therapy and Esophagectomy

医学 食管切除术 食管癌 内科学 新辅助治疗 切除术 肿瘤科 佐剂 辅助治疗 癌症 外科 梅德林 存活率 完全响应 普通外科 总体生存率 食管
作者
Yung Lee,Yasith Samarasinghe,Michael H. Lee,Luxmy Thiru,Yaron Shargall,Christian Finley,Wael Hanna,Oren Levine,Rosalyn Juergens,John Agzarian
出处
期刊:Annals of Surgery [Lippincott Williams & Wilkins]
卷期号:275 (1): 91-98 被引量:45
标识
DOI:10.1097/sla.0000000000005227
摘要

OBJECTIVE: The aim of this study was to analyze esophageal cancer patients who previously underwent neoadjuvant therapy followed by a curative resection to determine whether additional adjuvant therapy is associated with improved survival outcomes. SUMMARY BACKGROUND DATA: Neoadjuvant therapy followed by surgery is the standard of care for locally advanced esophageal cancer, whereas adjuvant therapy is typically employed for patients with residual disease. However, the role of adjuvant therapy after a curative resection is still uncertain. METHODS: MEDLINE, EMBASE, and CENTRAL databases were searched for studies comparing patients with esophageal cancer who underwent neoadjuvant therapy and curative resection with and without adjuvant therapy. Primary outcome was overall survival (OS), and random effects meta-analysis was conducted where appropriate. Grading of recommendations, assessment, development, and evaluation was used to assess the certainty of evidence. RESULTS: Ten studies involving 6462 patients were included. When compared to patients who received neoadjuvant therapy and esophagectomy alone, adjuvant therapy groups experienced a significant decrease in mortality by 48% at 1 year (Risk Ratio (RR) 0.52, 95% confidence interval [CI] 0.41-0.65, P < 0.001, moderate certainty). This reduction in mortality was carried through to 5-year follow-up (RR 0.91, 95% CI 0.86-0.96, P < 0.001, moderate certainty). The difference between the adjuvant therapy and the control group was uncertain regarding the secondary outcomes. CONCLUSION: Adjuvant therapy after neoadjuvant treatment and esophagectomy with negative resection margins provide an improved OS at 1 and 5 years with moderate to high certainty of evidence, but the benefit for disease-free survival and locoregional/distal recurrence remain uncertain due to limited reporting of these outcomes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
怡然蘑菇完成签到,获得积分10
刚刚
Dyying发布了新的文献求助10
刚刚
刚刚
慕青的应助被新嘟采纳,获得10
1秒前
ds发布了新的文献求助10
2秒前
4秒前
霸气乐荷完成签到 ,获得积分10
5秒前
哈哈哈完成签到 ,获得积分10
5秒前
学做科研发布了新的文献求助10
5秒前
纸杯蛋糕完成签到 ,获得积分10
6秒前
6秒前
温庭筠发布了新的文献求助10
7秒前
7秒前
油面摊子完成签到,获得积分10
7秒前
Cbdd_发布了新的文献求助10
11秒前
郑瑞欣发布了新的文献求助10
11秒前
秋瑾完成签到,获得积分10
12秒前
李爱国的应助被斯文雅旋采纳,获得10
12秒前
午夜小南瓜完成签到 ,获得积分10
12秒前
温庭筠完成签到,获得积分10
12秒前
一丢丢完成签到,获得积分10
13秒前
科研通AI65的应助被科研通管家采纳,获得20
13秒前
星辰大海的应助被科研通管家采纳,获得10
13秒前
丘比特的应助被科研通管家采纳,获得30
13秒前
毅然决然必然完成签到,获得积分10
13秒前
13秒前
14秒前
脑洞疼的应助被科研通管家采纳,获得10
14秒前
核桃的应助被科研通管家采纳,获得30
14秒前
共享精神的应助被科研通管家采纳,获得10
14秒前
大模型的应助被科研通管家采纳,获得10
14秒前
fantasy的应助被科研通管家采纳,获得10
14秒前
14秒前
小北完成签到,获得积分10
14秒前
14秒前
15秒前
fantasy的应助被科研通管家采纳,获得10
15秒前
科研通AI2S的应助被科研通管家采纳,获得10
15秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186875
求助须知:如何正确求助?哪些是违规求助? 9575211
关于积分的说明 21840004
捐赠科研通 7784592
什么是DOI,文献DOI怎么找? 3434866
关于科研通互助平台的介绍 2559266
邀请新用户注册赠送积分活动 2481717